Seegene

Seegene FCF/Debt

The Free Cash Flow to Debt Ratio of Seegene (096530.KQ) as of Oct 28, 2026 is 46,925.98 %. In the previous year, Free Cash Flow to Debt Ratio was 5,470.23 % — a change of 757.84% (higher).

FCF/Debt

46,925.98 %

YoY

757.84%

Last updated:

Free Cash Flow to Debt Ratio of Seegene is 2025 46,925.98 % . Free Cash Flow to Debt Ratio of Seegene was 2024 5,470.23 % . It decreases by 757.84% higher compared to the previous year.

The Seegene FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
108.21 KRW
Jan 1, 2019
152.90 KRW
Jan 1, 2020
202.95 KRW
Jan 1, 2021
171.23 KRW
Jan 1, 2022
160.66 KRW
Jan 1, 2023
4,429.63 KRW
Jan 1, 2024
5,470.23 KRW
Jan 1, 2025
46,925.98 KRW
The Seegene FCF/Debt history
YEARFCF/DebtYoY
46,925.98 %+757.84%
5,470.23 %+23.49%
4,429.63 %+2,657.16%
160.66 %-6.17%
171.23 %-15.63%
202.95 %+32.73%
152.90 %+41.30%
108.21 %+305.48%
26.69 %+127.85%
11.71 %-150.01%
-23.42 %-273.74%
13.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Free Cash Flow to Debt Ratio of Seegene is 46,925.98 % in 2025.

Free Cash Flow to Debt Ratio of Seegene changed from 5,470.23 % to 46,925.98 %, representing a 757.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Seegene since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Seegene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Seegene

All Key Metrics — Seegene